Pacer Advisors Inc. Purchases 4,056 Shares of DexCom, Inc. (NASDAQ:DXCM)

Pacer Advisors Inc. grew its position in DexCom, Inc. (NASDAQ:DXCM) by 7.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 55,174 shares of the medical device company’s stock after purchasing an additional 4,056 shares during the quarter. Pacer Advisors Inc.’s holdings in DexCom were worth $6,847,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also modified their holdings of the company. CVA Family Office LLC bought a new position in shares of DexCom in the fourth quarter worth approximately $100,000. HB Wealth Management LLC boosted its position in shares of DexCom by 65.5% in the fourth quarter. HB Wealth Management LLC now owns 5,001 shares of the medical device company’s stock worth $621,000 after purchasing an additional 1,980 shares during the period. Premier Path Wealth Partners LLC bought a new position in shares of DexCom in the fourth quarter worth approximately $325,000. Stableford Capital II LLC lifted its holdings in shares of DexCom by 2.1% in the fourth quarter. Stableford Capital II LLC now owns 4,367 shares of the medical device company’s stock worth $563,000 after buying an additional 88 shares in the last quarter. Finally, Oak Harvest Investment Services purchased a new position in shares of DexCom in the fourth quarter worth $1,318,000. 97.75% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other DexCom news, CFO Jereme M. Sylvain sold 3,363 shares of the stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $116.73, for a total transaction of $392,562.99. Following the transaction, the chief financial officer now directly owns 71,142 shares in the company, valued at approximately $8,304,405.66. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other DexCom news, CFO Jereme M. Sylvain sold 3,363 shares of the stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $116.73, for a total transaction of $392,562.99. Following the transaction, the chief financial officer now directly owns 71,142 shares in the company, valued at approximately $8,304,405.66. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Jereme M. Sylvain sold 2,734 shares of the firm’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $123.63, for a total transaction of $338,004.42. Following the completion of the sale, the chief financial officer now owns 74,505 shares in the company, valued at $9,211,053.15. The disclosure for this sale can be found here. Insiders have sold a total of 183,635 shares of company stock worth $24,020,621 in the last three months. Corporate insiders own 0.41% of the company’s stock.

DexCom Trading Down 0.3 %

NASDAQ DXCM opened at $139.48 on Thursday. The company’s 50-day moving average price is $125.31 and its 200-day moving average price is $111.84. The company has a current ratio of 2.84, a quick ratio of 2.48 and a debt-to-equity ratio of 1.18. The stock has a market cap of $53.77 billion, a PE ratio of 106.47, a PEG ratio of 2.41 and a beta of 1.18. DexCom, Inc. has a 12 month low of $74.75 and a 12 month high of $142.00.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, February 8th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.07. DexCom had a net margin of 14.95% and a return on equity of 28.31%. The company had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $1.02 billion. During the same period in the prior year, the business earned $0.34 EPS. The firm’s quarterly revenue was up 26.9% on a year-over-year basis. Equities research analysts forecast that DexCom, Inc. will post 1.76 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on DXCM shares. Piper Sandler boosted their target price on shares of DexCom from $135.00 to $150.00 and gave the stock an “overweight” rating in a report on Tuesday, December 19th. Morgan Stanley boosted their target price on shares of DexCom from $101.00 to $122.00 and gave the stock an “equal weight” rating in a report on Monday, December 4th. Royal Bank of Canada started coverage on shares of DexCom in a report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 target price on the stock. Raymond James boosted their target price on shares of DexCom from $147.00 to $151.00 and gave the stock a “strong-buy” rating in a report on Tuesday, January 23rd. Finally, StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a report on Tuesday. Three research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, DexCom has a consensus rating of “Moderate Buy” and a consensus target price of $136.67.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.